Hospital Universitario Hm Puerta Del Sur
- Address
- lock Available on a paid plan
Infectious Diseases and Vaccine Research
At Hospital Universitario Hm Puerta Del Sur, the strongest focus is on virus diseases and bacterial infections, with studies centered on prevention and immune protection. Research includes vaccines for COVID-19, cytomegalovirus infection, urinary tract infections, and group B streptococcus disease, aiming to improve protection against common and serious infections.
- Testing new vaccine approaches for SARS-CoV-2 and emerging variants
- Evaluating prevention of UTIs, CMV, and GBS in adults, pregnant women, and infants
- Assessing safety, tolerability, and immune response in prophylactic vaccine studies
This area reflects the site’s Vaccine Research Department expertise in building better tools to prevent infection across different age groups.
Neurology and Parkinson’s Disease
The site is actively involved in nervous system diseases, especially studies on Parkinson disease and related early-stage forms. These trials explore whether new therapies can slow symptom progression, improve motor function, and support longer-term safety in people living with the disease.
- Investigating treatments for early Parkinson’s disease and idiopathic Parkinson disease
- Studying options that may delay worsening of movement and daily function
- Monitoring safety and tolerability of emerging neurological therapies
The research also includes targeted approaches for specific patient groups, showing a strong interest in more personalized care for Parkinson’s disease.
Psychiatry, Sleep, and Pain Studies
Clinical research here also covers mental disorders and symptom-focused care, including treatment-resistant depression, insomnia disorder, chronic migraine, and acute pain. The goal is to find better ways to improve quality of life when standard care is not enough.
- Testing new options for treatment-resistant depression
- Evaluating therapies for pediatric insomnia and chronic migraine
- Studying pain relief strategies for post-operative acute pain
This mix of studies highlights an interest in both symptom control and patient-centered outcomes across psychiatry and neurology.
Oncology and Blood-Related Research
The site participates in trials within neoplasms and hemic and lymphatic diseases, focusing on cancer treatment support and complication prevention. Research includes high-risk HER2-positive breast cancer and cancer-associated thrombosis, with the aim of improving treatment effectiveness and reducing serious risks.
- Comparing cancer therapies for HER2-positive breast cancer
- Preventing cancer-associated thrombosis in patients receiving cancer care
- Supporting safer and more effective management of cancer-related complications
These studies show that Hospital Universitario Hm Puerta Del Sur contributes to both direct cancer treatment research and supportive care research.
Cardiovascular and Preventive Medicine
Research in cardiovascular diseases at this site includes prevention-focused studies that address clotting risk and overall patient safety. Rather than treating established heart disease alone, these trials look at ways to reduce complications in people undergoing other medical treatments.
- Evaluating prevention of thrombotic events in patients with cancer
- Studying treatment safety in populations at increased cardiovascular risk
- Exploring strategies that may lower serious treatment-related complications
This area connects cardiovascular medicine with broader preventive research across oncology and internal medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 73 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 71 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Pfizer Inc.2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario Hm Puerta Del Sur
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON’S DISEASE | UCB Biopharma | Phase II | Not Recruiting | Dec 2022 | Mar 2025 |
IMP list
lock Showing 1 of 73 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 3 | Unknown | 2022-02-03 | 2024-02-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.